Co-Diagnostics, Inc. (CODX)
NCM · Healthcare · Medical Devices
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 145K | 264K | 146K | 166K |
| Gross Profit | 119K | 122K | (48K) | 121K |
| Operating Income | (7.0M) | (7.7M) | (9.2M) | (6.2M) |
| Net Income | (5.9M) | (25.7M) | (9.1M) | (6.3M) |
| Diluted EPS | $-4.80 | N/A | $-4.06 | $-1.46 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 34.2M | 6.8M | 3.9M | 622K |
| Gross Profit | 28.7M | 2.6M | 2.9M | 400K |
| Operating Income | (11.6M) | (42.7M) | (40.1M) | (31.3M) |
| Net Income | (14.2M) | (35.3M) | (37.6M) | (46.9M) |
| Diluted EPS | $-13.50 | $-36.00 | $-37.22 | $-35.25 |